LISTED medicinal cannabis firm AusCann Group Holdings has appointed TGA-licensed PCI Pharma to produce its first product line, with the hard-shell capsules for chronic pain to launch in H1 2019.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Nov 18